Literature DB >> 12180535

Influence of structural variations in peptidomimetic 4-amidinophenylalanine-derived thrombin inhibitors on plasma clearance and biliary excretion in rats.

Jörg Hauptmann1, Torsten Steinmetzer, Helmut Vieweg, Peter Wikström, Jürg Stürzebecher.   

Abstract

PURPOSE: Systemic and hepato-biliary clearance of peptidomimetic thrombin inhibitors of the 4-amidinophenylalanine amide-type, derived from NAPAP (Nalpha-[2-naphthylsulfonyl-glycyl]-4-amidinophenylalanine-piperidide) by substituting Gly in P2 for natural and unnatural amino acids or by varying the C- and N-terminal moieties. resp., were investigated.
METHODS: Concentrations of the compounds administered as intravenous bolus injection at a dose of 1 mg/kg to bile duct-cannulated rats were determined in plasma and bile samples collected over 4 hours using reversed-phase HPLC.
RESULTS: NAPAP and the derivatives with additional charged groups are comparatively hydrophilic compounds. For NAPAP and most of the derivatives the biliary clearance accounted for a high percentage of the rapid systemic plasma clearance. Derivatives 2a-c with a second basic group in P2 position showed lower systemic and biliary clearance compared to NAPAP, whereas their cumulative biliary excretion after a period of 120 min was less affected. Bis-benzamidine derivatives 4a and 5 with the second amidino group in the N-terminal moiety had the lowest biliary clearance. Additional carboxylic groups reduced the systemic and biliary clearance only as free amidinophenylalanine carboxyl in 3a and 5. No influence compared to NAPAP was observed for 2d with a free carboxyl group in P2 position.
CONCLUSIONS: The weak correlation of the log P values of the compounds with the clearance parameters indicates the influence of structural variations, especially of charged groups, in this series of compounds rather than overall lipophilicity on hepato-biliary elimination mediated by hepatocellular transporters.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12180535     DOI: 10.1023/a:1016426724831

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  27 in total

1.  In vitro and in vivo comparison of arginine- and benzamidine-derived highly potent synthetic thrombin inhibitors.

Authors:  J Hauptmann; B Kaiser
Journal:  Pharmazie       Date:  1991-01       Impact factor: 1.267

Review 2.  Progress towards the discovery of orally active thrombin inhibitors.

Authors:  K Menear
Journal:  Curr Med Chem       Date:  1998-12       Impact factor: 4.530

Review 3.  Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor.

Authors:  M J Hursting; K L Alford; J C Becker; R L Brooks; J L Joffrion; G D Knappenberger; P W Kogan; T P Kogan; A A McKinney; R P Schwarz
Journal:  Semin Thromb Hemost       Date:  1997       Impact factor: 4.180

4.  Pharmacokinetics of argatroban in primates: evidence on endogenous uptake.

Authors:  S Ahmad; L H Yang; A Ahsan; K Fu; O Iqbal; D A Hoppensteadt; B E Lewis; J M Walenga; J Fareed
Journal:  Int Angiol       Date:  2000-06       Impact factor: 2.789

5.  Structure-activity relationships of new NAPAP-analogs.

Authors:  T Steinmetzer; A Schweinitz; S Künzel; P Wikström; J Hauptmann; J Stürzebecher
Journal:  J Enzyme Inhib       Date:  2001

6.  Quantitative structure-pharmacokinetics relationships: I. Development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the rat.

Authors:  G E Blakey; I A Nestorov; P A Arundel; L J Aarons; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1997-06

7.  First-pass elimination of a peptidomimetic thrombin inhibitor is due to carrier-mediated uptake by the liver. Interaction with bile acid transport systems.

Authors:  U Eckhardt; W Stüber; G Dickneite; M Reers; E Petzinger
Journal:  Biochem Pharmacol       Date:  1996-07-12       Impact factor: 5.858

8.  Design and synthesis of potent and highly selective thrombin inhibitors.

Authors:  K Hilpert; J Ackermann; D W Banner; A Gast; K Gubernator; P Hadváry; L Labler; K Müller; G Schmid; T B Tschopp
Journal:  J Med Chem       Date:  1994-11-11       Impact factor: 7.446

9.  Pharmacological characterization of a new structural variant of 4-amidinophenylalanine amide-type synthetic thrombin inhibitor.

Authors:  J Hauptmann; B Kaiser; M Paintz; F Markwardt
Journal:  Pharmazie       Date:  1989-04       Impact factor: 1.267

10.  Pharmacological characterization of a new 4-amidinophenyl-alanine thrombin-inhibitor (CRC 220).

Authors:  G Dickneite; D Seiffge; K H Diehl; M Reers; J Czech; E Weinmann; D Hoffmann; W Stüber
Journal:  Thromb Res       Date:  1995-02-15       Impact factor: 3.944

View more
  2 in total

Review 1.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

2.  Thrombin inhibitors identified by computer-assisted multiparameter design.

Authors:  Daniel Riester; Frank Wirsching; Gabriela Salinas; Martina Keller; Michael Gebinoga; Stefan Kamphausen; Christian Merkwirth; Ruediger Goetz; Martin Wiesenfeldt; Jörg Stürzebecher; Wolfram Bode; Rainer Friedrich; Marcel Thürk; Andreas Schwienhorst
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-03       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.